Silexion Therapeutics enters inducement agreement for exercise of ~2M warrants at $0.50, raising ~$1M

Silexion Therapeutics Corp

Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.
Gross proceeds of approximately $1.0 million expected from the warrant exercise, with H.C. Wainwright as placement agent earning 7% cash fee.
Company will issue new Series C (2,045,000) and Series D (1,945,184) warrants exercisable at $0.50, totaling 3,990,184 new warrant shares.
Closing expected on or about May 18, 2026, with net proceeds used for general corporate purposes.
Placement agent also receives warrants to purchase up to 139,656 ordinary shares at $0.625 per share.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Silexion Therapeutics Corp entered into Inducement Letter with certain holders valued at approximately $1.0 million (effective 2026-05-15).

Action: entry
Agreement: equity purchase
Counterparty: certain holders
Value: approximately $1.0 million
Effective: 2026-05-15

Exact text from the filing

On May 15, 2026, Silexion Therapeutics Corp (“ Silexion ” or the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (each a “ Holder ”) of 1,995,092 of the Company’s existing warrants

View on SEC.gov

154 material agreements filed in the last 30 days. Browse all material agreements →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-26-002739

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.